Get the Stockscreener App
0.9705
1.09%
0.0105
Barinthus Biotherapeutics Plc Adr stock is traded at $0.9705, with a volume of 12,678.
It is up +1.09% in the last 24 hours and down -3.91% over the past month.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
See More
Previous Close:
$0.96
Open:
$1.09
24h Volume:
12,678
Relative Volume:
0.25
Market Cap:
$39.04M
Revenue:
$13.42M
Net Income/Loss:
$-73.35M
P/E Ratio:
-0.5055
EPS:
-1.92
Net Cash Flow:
$-56.34M
1W Performance:
-10.14%
1M Performance:
-3.91%
6M Performance:
-18.45%
1Y Performance:
-63.92%
1-Day Range:
$0.96
$1.14
1-Week Range:
$0.945
$1.15
52-Week Range:
$0.8008
$4.1591
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
Name
Barinthus Biotherapeutics Plc Adr
Sector
Industry
Phone
44 (0) 1865 818808
Address
UNIT 6-10, ZEUS BUILDING, DIDCOT
Compare BRNS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRNS
Barinthus Biotherapeutics Plc Adr
|
0.9705 | 39.04M | 13.42M | -73.35M | -56.34M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | Morgan Stanley | Overweight |
| May-25-21 | Initiated | William Blair | Outperform |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Latest News
Dollar General Corp (DG) Shares Up Despite Recent Market Volatility - The News Heater
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Strong Buy: Here's Why - MSN
Exclusive-Mexico's Pemex, billionaire Slim renegotiate deepwater gas project - Yahoo Finance
RBC raises Reckitt Benckiser stock target to £57.00, keeps outperform - MSN
Stocks Generating Improved Relative Strength: Revolution Medicines - MSN
Barinthus Bio shifts focus, cuts workforce to extend cash runway - Investing.com
New trial shows promise for chronic hepatitis B treatment - Investing.com India
Barinthus Bio completes enrollment for two clinical trials - Investing.com India
Barinthus Bio intiates Phase 1 clinical trial of VTP-1000 for treatment of coeliac disease - European Pharmaceutical Manufacturer
Barinthus Bio launches Phase 1 celiac disease therapy trial - Investing.com
Barinthus Biotherapeutics Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease - Investing.com
Barinthus Biotherapeutics appoints new COO - Investing.com
BRNS Stock Touches 52-Week Low at $1.14 Amid Market Challenges - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Vaccitech (VACC) Stock Price, News & Analysis - MarketBeat
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):